Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.21 EPS on August, 8.They anticipate $0.07 EPS change or 50.00% from last quarter’s $-0.14 EPS. After having $-0.23 EPS previously, ChemoCentryx, Inc.’s analysts see -8.70% EPS growth. The stock increased 0.13% or $0.01 during the last trading session, reaching $7.75. About 43,116 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 11.16% since July 29, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical CCXI News: 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018
Blackrock Muniyield California Quality Fund Inc (MCA) investors sentiment decreased to 0.95 in Q1 2019. It’s down -1.28, from 2.23 in 2018Q4. The ratio dived, as 18 institutional investors increased or started new holdings, while 19 sold and reduced their stock positions in Blackrock Muniyield California Quality Fund Inc. The institutional investors in our database now possess: 5.74 million shares, down from 6.04 million shares in 2018Q4. Also, the number of institutional investors holding Blackrock Muniyield California Quality Fund Inc in top ten holdings increased from 0 to 1 for an increase of 1. Sold All: 7 Reduced: 12 Increased: 14 New Position: 4.
Investors sentiment increased to 1.44 in 2019 Q1. Its up 0.51, from 0.93 in 2018Q4. It increased, as 12 investors sold ChemoCentryx, Inc. shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Matarin Mngmt Ltd Limited Liability Company has invested 0.08% in ChemoCentryx, Inc. (NASDAQ:CCXI). Walleye Trading Ltd Liability Corp holds 14,800 shares or 0% of its portfolio. Dimensional Fund L P owns 1.19M shares. Consonance Cap L P reported 1.67M shares or 1.46% of all its holdings. Pnc Fincl Services Group reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). The California-based Charles Schwab Invest Mgmt has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Bvf Il accumulated 1.46M shares or 2.28% of the stock. Alps Advisors invested in 122,039 shares or 0.01% of the stock. Dorsey Wright Associates owns 585 shares. Smith Asset Grp Limited Partnership has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 21,617 shares. Sectoral Asset Mngmt Incorporated reported 0.03% in ChemoCentryx, Inc. (NASDAQ:CCXI). 4,696 were reported by Bnp Paribas Arbitrage. Millennium Mgmt Limited Liability Co reported 49,812 shares or 0% of all its holdings. State Common Retirement Fund stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). State Of Wisconsin Inv Board invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI).
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint – Benzinga” on July 26, 2019, also Finance.Yahoo.com with their article: “Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI) – Yahoo Finance” published on May 09, 2019, Seekingalpha.com published: “InflaRx downdraft engulfs ChemoCentryx, down 28% premarket – Seeking Alpha” on June 05, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights – GlobeNewswire” published on May 06, 2019 as well as Globenewswire.com‘s news article titled: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” with publication date: March 28, 2019.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $449.87 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 6 analyst reports since February 11, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, March 27 by FBR Capital. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 12. Leerink Swann initiated the stock with “Buy” rating in Thursday, February 14 report.
BlackRock MuniYield California Quality Fund, Inc. is a closed ended fixed income mutual fund launched by BlackRock, Inc. The company has market cap of $492.69 million. It is managed by BlackRock Advisors, LLC. It has a 71.24 P/E ratio. The fund invests in fixed income markets.
Mariner Investment Group Llc holds 2.49% of its portfolio in BlackRock MuniYield California Quality Fund, Inc. for 136,771 shares. Hollencrest Capital Management owns 747,326 shares or 1.32% of their US portfolio. Moreover, Dakota Wealth Management has 0.76% invested in the company for 63,599 shares. The New York-based Karpus Management Inc. has invested 0.45% in the stock. Rivernorth Capital Management Llc, a Illinois-based fund reported 488,489 shares.
The stock increased 0.28% or $0.04 during the last trading session, reaching $14.32. About 5,437 shares traded. BlackRock MuniYield California Quality Fund, Inc. (MCA) has risen 5.16% since July 29, 2018 and is uptrending. It has outperformed by 0.73% the S&P500.
More notable recent BlackRock MuniYield California Quality Fund, Inc. (NYSE:MCA) news were published by: Seekingalpha.com which released: “BlackRock MuniYield California Insured Fund declares $0.0460 dividend – Seeking Alpha” on July 02, 2019, also Seekingalpha.com with their article: “Shopify: A Multibagger That I Don’t Own Anymore – Seeking Alpha” published on February 06, 2019, Seekingalpha.com published: “Shopify: Expensive Beyond Reason – Seeking Alpha” on September 11, 2018. More interesting news about BlackRock MuniYield California Quality Fund, Inc. (NYSE:MCA) were released by: Finance.Yahoo.com and their article: “Have Insiders Been Buying Murray Cod Australia Limited (ASX:MCA) Shares? – Yahoo Finance” published on July 16, 2019 as well as Seekingalpha.com‘s news article titled: “In Search Of Income: Municipal Bond CEFs (Part II) – Seeking Alpha” with publication date: January 20, 2015.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.